AR1001
AriBio
PDE5 inhibitor pill
Phase 3 in 1,535 patients across 13 countries finished. Results due 16 Nov 2026.
Results: 16 Nov 2026
Neurodegenerative · memory
Alzheimer's
Two antibodies already slow early disease without stopping it. Research now tests easier-to-use versions, anti-tau drugs and even a Viagra-like pill.
- Cure
- None yet
- Current treatment
- Symptom drugs and anti-amyloid antibodies
- Who has it
- Over 55 million with dementia worldwide
- Updated
7candidates on the board
Phase 3furthest phase
3updates in 2026
What changed
The latest developments, newest first.
Coming upAR1001 phase 3 results
The first phase 3 pill expected to report this year, at CTAD in Boston.
ProgressLeqembi gets an at-home starting dose
FDA approved at-home injection. Real-world study: over 80% stable after 17 months.
StoppedTwo candidates fail
Ceperognastat (Lilly) lowered tau without helping memory; valiltramiprosate failed phase 3.
ProgressAgitation drug approved
Auvelity becomes the second drug approved for Alzheimer's agitation.
Treatments in development
Each column is a step on the road to the pharmacy. Colors show the type of treatment.
- Antibody or biologic (3)
- Oral drug (2)
- Cell, gene or RNA therapy (1)
- Vaccine, device or other (1)
Phase 3confirmation · 4
Trontinemabe
Roche
Brain-shuttle anti-amyloid
Clears plaque fast with less brain swelling. Phase 3 trials for treatment and prevention.
In phase 3
Remternetug
Eli Lilly
Next-gen anti-amyloid
IV and injectable forms. Cognitive-decline study ends in 2029.
Through 2029
Spectris
Cognito Therapeutics
Headset with light and sound
Stimulates the brain at a specific frequency. Phase 3 in 670 people.
Data: 2026
Phase 2efficacy and dose · 3
Diranersen
Biogen
RNA therapy against tau
Missed its main goal but lowered tau; may advance to phase 3.
Data: Jul 2026
Etalanetug
Eisai
Anti-tau antibody
Lowered tau in genetic Alzheimer's. Phase 2/3.
In phase 2/3
PRI-002
Priavoid
Pill that breaks up amyloid
No swelling or microbleeds so far. 304 participants.
Ends: Dec 2026
Left behind
Candidates that looked promising and were stopped. Most treatments tested never reach the market.
Ceperognastat
2026 · Lilly; lowered tau but not decline.
Valiltramiprosate
2026 · Alzheon; failed phase 3 in ApoE4 carriers.
Semaglutida (EVOKE)
2025 · Novo Nordisk; Ozempic did not slow Alzheimer's.
Frequently asked questions
Is there a cure for Alzheimer's?
None yet. Current treatment: Symptom drugs and anti-amyloid antibodies.
Which Alzheimer's treatments are being tested?
Fasevia tracks 7 candidates: AR1001 (Phase 3); Trontinemabe (Phase 3); Remternetug (Phase 3); Spectris (Phase 3); Diranersen (Phase 2); Etalanetug (Phase 2); PRI-002 (Phase 2).
What is the most advanced Alzheimer's treatment in development?
The furthest along today is AR1001 (AriBio), in phase 3. Phase 3 in 1,535 patients across 13 countries finished. Results due 16 Nov 2026.
When could a new Alzheimer's treatment arrive?
A drug has to complete phase 3 and be reviewed by health agencies such as the FDA or EMA, which usually takes several years. The leading candidate today is in phase 3.